Page 190 - Aet News Today

For anyone suffering from a debilitating or life-threatening disease, the experience of procuring specialty medications is like having a second job. You are your own advocate working in a draconian system that was developed as a business, not a care service. When you’re finally successful, after what can be weeks of delays, you’re met with high costs. This is a pattern patients get used to as a result of their illness being chronic. The prescribing of specialty medications by a physician in...

HLTH Foundation Executive Director Janna Guinen described its focus on promoting equity, inclusion and opportunity in healthcare on behalf of patients, healthcare professionals and health tech entrepreneurs.

Epic, Nordic, Impact Advisors, The Chartis Group and Medasource were the five companies with the best performances in this year’s Best in KLAS Awards. KLAS Research named Epic as the top overall software suite for the thirteenth year in a row.

Rumors of the deal first surfaced in January, with some dismissing the idea. Several experts say the deal makes sense for CVS Health, as it looks to expand into primary and value-based senior care.

High prices have drawn other critics, as well, including President Joe Biden. He renewed his call for a broad price cap during his annual State of the Union address. Pharma companies insist they have been part of the solution.

London-based Unmind offers a measurement tool that allows employees to gain insights into their own mental health. Its content library also provides access to exercises and self-guided courses. Dublin-based Frankie Health, meanwhile, connects employees to a global network of mental health practitioners. The combined organization's new product, Unmind Talk, joins the strengths of both companies.

ShiftMed, an online marketplace for W-2 healthcare workers, recently raised $200 million in funding. The company's platform allows providers to post their open shifts in hopes they will be filled by local nurses.

A Johnson & Johnson drug acquired as part of a $6.5 billion deal has preliminary data showing it met the main goal of a mid-stage test in a rare blood disorder that can become fatal to fetuses. Full data from the trial will be presented at a future scientific meeting.

ReKlame Health launched in 2020 to provide affordable, culturally competent behavioral healthcare to Black and Brown communities in New York. On Monday, the startup announced it is now serving patients in two additional states — New Jersey and Florida.

AstraZeneca dominates the market for drugs that treat rare blood disorder paroxysmal nocturnal hemoglobinuria. Roche drug crovalimab met the two main goals of its pivotal test, and if approved, would offer a dosing edge compared to AstraZeneca’s two blockbuster PNH medicines.